Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshimasa Kihana is active.

Publication


Featured researches published by Toshimasa Kihana.


Japanese Journal of Cancer Research | 1992

High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy

Toshimasa Kihana; Hitoshi Tsuda; Shinichi Teshima; Shuichi Okada; Shumpei Matsuura; Setsuo Hirohashi

Using the poylmerase chain reaction and single‐strand conformation polymorphism analysis, p53 gene mutations were examined in 24 cases of ovarian tumor including 14 ovarian carcinomas and 2 borderline cases of common epithelial type, 7 germ cell tumors, and one stromal tumor. Abnormal bands indicating mutations were detected in 12 (50%) of the cases examined, being present most frequently in common “epithelial” ovarian carcinoma (71%, 10/14). One case each of squamous cell carcinoma originating in a dermoid cyst and anaplastic dysgerminoma were positive for mutation. Direct sequencing confirmed 12 mutations and revealed G→A and G→C nucleotide changes in 5 and 3 cases (42% and 25%), respectively. The mutation was localized at the CpG site of the gene in 3 cases. Immunohistochemical examination of p53 protein in 21 cases and DNA flow‐cytometrical analysis in 17 cases were also performed. Nuclear accumulation of the p53 protein and DNA aneuploidy pattern were detected in 11 (52%) and 9 (53%) cases, respectively. These were significantly correlated with p53 gene mutation (P<0.01 and P<0.05, respectively; Fishers exact test). Neither mutation of the p53 gene, nuclear accumulation of p53 protein nor DNA aneuploidy was detected in borderline cases of common “epithelial” type, typical dysgerminoma and immature teratoma. These results suggest that p53 gene mutation, nuclear accumulation of the protein and the DNA aneuploidy pattern are events occurring almost simultaneously in the progression of ovarian tumors, and that p53 abnormalities seem to be correlated with a high grade of malignancy.


Japanese Journal of Cancer Research | 1991

Point Mutation of c‐Ki‐ras Oncogene in Gastric Adenoma and Adenocarcinoma with Tubular Differentiation

Toshimasa Kihana; Hitoshi Tsuda; Teruyuki Hirota; Yukio Shimosato; Hiromi Sakamoto; Masaaki Terada; Setsuo Hirohashi

The presence of point mutation at codons 12,13 and 61 of the c‐Ki‐ras oncogene was investigated in 7 cases of gastric adenoma and 35 cases of gastric adenocarcinoma using DNA samples from formalin‐fixed and paraffin‐embedded tissues. Oligonucleotides encompassing the three codons were amplified by using the polymerase chain reaction (PCR), and then examined for point mutation by the selective oligonucleotide hybridization technique. Point mutation was detected in three of the 7 adenomas (43%) and three of the 35 carcinomas (9%). All the gastric adenomas showed the histology of tubular adenoma, being very similar to that of colonic adenoma. The 35 cases of gastric adenocarcinoma were classified into 17 cases of differentiated type and 17 cases of undifferentiated type including signet‐ring cell carcinoma. The point mutation of c‐Ki‐ras oncogene was detected only in the differentiated type (3/17, 18%), and there was no case with point mutation in the undifferentiated type. These results suggest that the genetic mechanism of carcinogenesis differs between the differentiated type and the undifferentiated type of gastric adenocarcinoma, and also that c‐Ki‐ros activation is possibly involved in a relatively early step of the “adenoma‐carcinoma sequence,” which leads to the development of a portion of differentiated adenocarcinomas in the stomach.


Molecular Carcinogenesis | 1996

Incidence of p53 and Ha‐ras gene mutations in chemically induced rat mammary carcinomas

Katsumi Kito; Toshimasa Kihana; Atsuro Sugita; Shinichi Murao; Shun Akehi; Motomichi Sato; Mari Tachibana; Shigeru Kimura; Norifumi Ueda

To determine whether p53 alterations, which are frequent in human breast cancers, are also common in rat mammary tumors, we examined 40 tumors from 24 rats treated with 7,12‐dimethylbenz[a]anthracene (DMBA) and 34 tumors from 14 rats treated with N‐nitroso‐N‐methylurea (NMU) (an N‐nitroso compound). DMBA and NMU are known genotoxic mutagens. The entire coding regions of the p53 and Ha‐ras genes were examined for mutations by polymerase chain reaction single‐strand conformational polymorphism analysis and by direct sequencing. One of the 40 DMBA‐induced mammary tumors had a p53 mutation, a single‐base substitution (???AGC→???GGC) at codon 307, resulting in an amino‐acid change from Ser to Gly. No mutations were found in NMU‐induced tumors. The incidence of Ha‐ras gene mutation was 79% (27 of 34) at codon 12 in the NMU group and 23% (nine of 40) at codon 61 in the DMBA group. Thus, p53 mutation, in contrast to Ha‐ras mutation, did not seem to be a prerequisite for carcinogenesis in chemically induced rat mammary tumors.


Pathology International | 1997

Modulation of S‐100 genes response to growth conditions in human epithelial tumor cells

Takashi Matsumoto; Shinichi Murao; Katsumi Kito; Toshimasa Kihana; Shumpei Matsuura; Norifumi Ueda

Many new members of the S‐100 genes are known to be associated with cell differentiation, malignant transformation, and cell cycle. Of the S‐100 genes examined In the present study, calcyclin, calpactin I light chain and calvasculln were expressed In most human epithellal tumor cells, and their expression levels differed according to various growth conditions. Their transcribed levels differed depending on each cell line, but their expression patterns were similarly changed under growth‐modulatory conditions. Their messenger RNA levels increased parallel to the S phase population of cells, and decreased at G1/G2 phases. In contrast, this expression diminished in tumor cells under growth‐Inhibitory conditions, such as treatment with topolsomerase II inhibitor VP‐16 or phorbol 12‐myristate 13‐acetate.


Japanese Journal of Cancer Research | 1996

Allelic Loss of Chromosome 16q in Endometrial Cancer: Correlation with Poor Prognosis of Patients and Less Differentiated Histology

Toshimasa Kihana; Naoki Yano; Shinichi Murao; Haruhiko Iketani; Katsuyuki Hamada; Jyuri Yano; Shumpei Matsuura

Deletion of certain chromosomal regions can be demonstrated in malignant cells. Chromosome 16q is one of the regions where allelic loss is frequently detected in carcinoma of the breast and many other tumors, suggesting that gene(s) which retard tumor growth may exist here. To elucidate the clinico‐pathological significance of chromosome 16q, loss of heterozygosity (LOH) was investigated using microsatellite polymorphism analysis in 58 patients with endometrial lesions (50 with endometrial carcinoma and 8 who had hyperplasia with or without atypia). When 11 regions of chromosome 16q were examined, LOH was found in 20 patients with carcinoma (40%) and none of the patients with hyperplasia. The tumors of 9 of the 20 patients (45%) showed total loss of 16q, while the others (55%) showed partial deletion. Tumors with LOH were histologically less differentiated than those without LOH (P=0.038, χ2 test). Patients with tumors showing LOH of 16q had a worse prognosis than those without LOH according to Kaplan‐Meier survival analysis (P=0.0158, log‐rank test). In addition, LOH of 16q showed a significant relationship to prognosis by Cox regression analysis. Deletion mapping of 16q demonstrated that two regions (16q22.1 and 16q22.2‐23.1) were frequently involved. Patients with 16q22.1 LOH had a poorer prognosis than those with intact 16q22.1 (P=0.0003, log‐rank test). These findings suggest that gene(s) of which defect is possibly related to the aggressiveness of endometrial cancer are localized on a limited region of 16q that includes 16q22.1.


Gynecologic and Obstetric Investigation | 2002

Severe Allergy in a Pregnant Woman after Vaginal Examination with a Latex Glove

Yuri Shingai; Koji Nakagawa; Takeshi Kato; Toru Fujioka; Takashi Matsumoto; Toshimasa Kihana; Kiyofumi Noda; Takashi Mori

Recently case reports about latex allergy were increased. We have experienced severe latex allergy in a pregnant women after vaginal examination with a latex glove. A 33-year-old woman, 38 weeks pregenant, was hospitalized for management of fetal IUGR. She underwent a vaginal examination with a latex glove and soon developed severe anaphylactic reactions. Although two hours later her condition had remarkably improved, regular uterine contractions appeared, and fetal cardiotocogram showed late decelerations. So emergency cesarean section was performed under the situation without using any latex products. She delivered a male infant weighing 2,227 g (–2.21 SD) at 38 weeks gestation. His Apgar score was 5 points at 1 min and 8 points at 5 min. The latex-specific IgE of this patient was high and IgE for banana, avocado and kiwi were also positive. These foods showed cross-reactions with latex, but she had no history of allergic reactions against these foods. She had a history of atopic reactions and of atopic dermatitis while working as a nurse at the ICU. It is thought that this patient was in the high-risk group.


Japanese Journal of Cancer Research | 1998

Association of Replication Error Positive Phenotype with Lymphocyte Infiltration in Endometrial Cancers

Toshimasa Kihana; Toru Fujioka; Katsuyuki Hamada; Katsumi Kito; Akira Takahashi; Choutatsu Tsukayama; Masaharu Ito

Microsatellite instability (MI) has been detected in certain sporadic cancers as well as in hereditary non‐polyposis colorectal cancer (HNPCC). In order to determine the precise clinicopathological characteristics of MI in endometrial cancer, we examined 90 sporadic endometrial cancers (83 endometrioid adenocarcinomas, 3 adenosquamous carcinomas, 3 papillary serous carcinomas, and 1 clear cell carcinoma) and eight lesions of endometrial hyperplasia for replication error (RER) using polymerase chain reaction amplification of CA repeated microsatellite sequences at 15 loci. RER was observed in 23 (28%) of the 83 endometrioid adenocarcinomas at at least one locus and in 19 (23%) at two or more loci (RER+ phenotype) in the seven most commonly observed loci, but not in carcinomas of other histological types or in endometrial hyperplasia. Lymphocyte infiltration around carcinoma cells, which is one of the histological features seen in tumors from HNPCC, was severer in RER+ phenotype tumors (79%, 11/14) than in the RER– tumors (25%, 11/44) (marked/moderate infiltration versus slight, P<0.001, χ2 test), when 58 tumors with muscular invasion were examined. The RER+ phenotype was associated with a higher parity and gravidity (P<0.05, Wilcoxon test). However, RER+ phenotype was not associated with tumor stage, histological grade, muscular invasion, lymph node metastasis or patient survival. In conclusion, MI occurs in a subset of endometrial cancers, which often show marked infiltration of lymphocytes around the tumor.


International Urogynecology Journal | 1999

Urinary Disturbance after Therapy for Cervical Cancer: Urodynamic Evaluation and β2-Agonist Medication

Katsuyuki Hamada; Toshimasa Kihana; M. Kataoka; S. Yoshioka; S. Nishio; Shumpei Matsuura; Masaharu Ito

Abstract: Urinary disturbance frequently develops following therapy for cervical cancer; however, no effective medical treatment has so far been reported. Sixty-five patients who developed urinary disturbance after radiation therapy, radical hysterectomy or radical hysterectomy with radiation therapy for cervical cancer underwent urodynamic assessment. Those who underwent radical hysterectomy with radiation therapy experienced the most severe urine loss, as determined by the pad test. All patients showed markedly reduced bladder compliance. A β2-agonist (mabuterol) significantly improved compliance, bladder capacity and flow rate. It is suggested that medication with mabuterol is a potential novel approach to the treatment of urinary disturbance after therapy for cervical cancer.


International Urogynecology Journal | 1994

Treatment with β2-agonist for severe bladder dysfunction due to high-dose irradiation after radical hysterectomy

Katsuyuki Hamada; Toshimasa Kihana; Shumpei Matsuura; M. Kataoka; S. Yoshioka; S. Nishio; H. Iwata

A case of severe bladder dysfunction due to a high-dose irradiation of 180 Gy after radical hysterectomy for cervical cancer is presented. The patient had suffered from urinary disturbances for 11 years after operation and radiation therapy. The results of urodynamic studies were low capacity, low compliance and low urethral pressure. The β2-agonist mabuterol was administered for 3 years. Bladder capacity, compliance and urethral closure pressure improved significantly after the treatment. The voided volume increased significantly to twice the pretreatment state. Frequency, incontinence and urine loss by the 60-minute padweighing test decreased significantly to one-third to one-fifth of the pretreatment state. The patient is doing well without any side effects 3 years after initiation of the treatment.


Cancer Research | 1991

Detection of Frequent p53 Gene Mutations in Primary Gastric Cancer by Cell Sorting and Polymerase Chain Reaction Single-Strand Conformation Polymorphism Analysis

Gen Tamura; Toshimasa Kihana; Kazuhiro Nomura; Masaaki Terada; Takashi Sugimura; Setsuo Hirohashi

Collaboration


Dive into the Toshimasa Kihana's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Setsuo Hirohashi

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hitoshi Tsuda

National Defense Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge